Director Roeland Nusse sold 10,400 shares of Bio-Techne Corp (NASDAQ:TECH) stock on March 7, 2024, according to recent SEC filings. The trade was executed at an average price of $76.98 per share for his total value of $800,672.
Bio-Techne Corp is a global life sciences company providing innovative tools and bioactive reagents to the research and clinical diagnostic communities. The company's products are essential in the fields of genomics, protein analysis and expression, cell analysis, drug discovery, and manufacturing of biologically-based therapeutics and diagnostics.
Over the past year, Roeland Nusse sold a total of 19,339 shares of Bio-Techne Corp stock, but did not buy any shares. Bio-Techne Corp's insider trading history shows that there were no insider buys in the past year, but he had 4 insider sells in the same period.
In terms of valuation, on the day of the most recent insider sale, Biotechne Inc.'s stock was trading at $76.98, giving the company a market capitalization of $11.81 billion. His price-to-earnings ratio of 54.44 is higher than the industry median of 28.96 and also higher than the company's historical median price-to-earnings ratio.
With a price of $76.98 and a GF value of $92.23, Bio-Techne Corp's price to GF value ratio is 0.83, indicating the stock is slightly undervalued, according to GuruFocus Value.
GF Value is an estimate of intrinsic value that takes into account historical trading multiples, GuruFocus adjustment factors based on the company's past earnings and growth, and Morningstar analyst forecasts of future earnings.
The recent insider selling by Director Rolando Nusse may provide investors with an opportunity to re-evaluate their position in Biotechne Corp. in light of the company's valuation metrics and insider trading activity.
For further information regarding insider transactions and the company's finances, interested parties should refer to the entire SEC filing.
This article created by GuruFocus is intended to provide general insight and is not intended as financial advice. Our commentary is based on historical data and analyst forecasts using an unbiased methodology and is not intended to serve as specific investment guidance. It does not constitute a recommendation to buy or sell stocks, and does not take into account your individual investment objectives or financial situation. Our objective is to provide fundamental data-driven analysis over time. Please note that our analysis may not incorporate the latest announcements or qualitative information from price-sensitive companies. GuruFocus has no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
